SIGIRR and cancer: Interestingly, TIR8, a receptor that belongs to the IL-1 family, has recently emerged as a novel NK cell immune checkpoint in cancer and further investigation is ongoing to verify whether genetic manipulation of this receptor may be exploited for cancer therapy.